Reducing the Burden and Transforming Outcomes for Patients With Beta Thalassemia
Webcast
1.5 AMA PRA Category 1 Credits™ ...OVERVIEW
Reducing the Burden and Transforming Outcomes for Patients With Beta Thalassemia is organized by i3 Health.
Start Date: June 16, 2026
End Date: June 15, 2027
Description:
Beta thalassemia is a rare genetic disorder characterized by impaired hemoglobin synthesis and chronic anemia, historically requiring lifelong transfusion and iron chelation protocols. While these conventional treatments are life-saving, they impose a heavy time, treatment, and quality-of-life burden on patients. With gene editing therapies and a rapidly expanding pipeline of novel disease-modifying agents, the multidisciplinary team faces a new clinical landscape. These breakthroughs offer the potential for reduced transfusion burden or even transfusion independence, but they bring complex considerations regarding regimen individualization, lifelong care planning, and long-term safety (Njeim et al, 2024; Hu et al, 2024). To optimize care from childhood through adulthood, the multidisciplinary team must be equipped to personalize treatment for patients using shared decision making. This Interactive Case Consult features Hanny Al-Samkari, MD, the Peggy S. Blitz Endowed Chair in Hematology/Oncology and the Co-Director of the Hereditary Hemorrhagic Telangiectasia Center at Massachusetts General Hospital, and Sherif Badawy, MD, MS, MBA, the Director of the Comprehensive Adult and Pediatric Thalassemia Program at Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, as they explore evidence-based strategies for reducing treatment burden and transforming outcomes for patients with beta thalassemia.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Apply monitoring and management strategies that ensure adequate chelation for patients with beta thalassemia.
- Evaluate the clinical utility of current and emerging treatments for transfusion-dependent beta thalassemia (beta TDT) and non–transfusion-dependent beta thalassemia (beta NTDT).
- Appraise strategies to optimize therapeutic selection and implementation for individual children, adolescents, and adults with beta thalassemia.
ACCREDITATION & CREDITS
Credits:
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians:
i3 Health designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants/Associates:
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 6/15/27. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners:
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development:
A maximum of 1.5 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 1.5 contact hours of pharmacology credit for Advanced Practice Registered Nurses.Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.5 ANCC contact hours.
Continuing Pharmacy Education:
i3 Health has approved this knowledge-based activity for 1.5 ACPE CE hours. The Universal Activity Number for this activity. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion.
TARGET AUDIENCE
PharmacistHealthcare ProfessionalsNursesHematologistAdvanced Practice Providers Other Healthcare ProfessionalsSPECIALITIES
HaematologyOncology
Download eMedEvents Mobile App
Track your CE certificates and CME requirements anytime, anywhere.
Quick Links